Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07458347). This is a study registration, not published results. Lead sponsor: Kestrel Therapeutics, Inc.. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 545 participants (ESTIMATED). Conditions: KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors. Interventions: DRUG: KST-6051; DRUG: Gemcitabine/nab-paclitaxel; DRUG: Cetuximab; DRUG: Pembrolizumab; DRUG: mFOLFOX6; DRUG: FOLFIRI; DRUG: Pemetrexed; DRUG: Carboplatin. Primary outcome measures: Dose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days) , Up to Day 21 of Treatment Cycle 1; Dose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) , Up to approximately 2 years; Dose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs) , Up to approximately 2 years; Dose Expansion Cohorts: Confirmed Objective Response Rate (ORR) , Up to approximately 2 years. Brief summary: The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.